Search for Cases

Case Details

Case Code: BSTR569
Case Length: 10 Pages 
Period: 2013 - 2018   
Pub Date: 2019
Teaching Note: Available
Price: Rs.300
Organization : BenevolentAI
Industry :Pharmaceutical
Countries : United Kingdom
Themes: Disruptive Innovation/Incremental Innovation/Strategic Innovation/Breakthrough Innovation/Traditional Drug Discovery Process/
Case Studies  
Business Strategy
Marketing
Finance
Human Resource Management
Technology
Operations
Economics
Leadership & Entrepreneurship

BenevolentAI – Using AI to Disrupt Traditional Drug Discovery Process

 
<<Previous Page 

INTRODUCTION

 
On April 19, 2018, BenevolentAI (BAI), the largest Artificial Intelligence (AI) company in the private sector in Europe and among the top five privately owned AI companies in the world, raised US$115 million in its latest round of funding from investors. With this massive funding, BAI increased its market valuation to US$2 billion and planned to scale up its drug development and its AI platform, the ‘Bioscience Machine Brain’ (BMB). In June 2018, BAI was awarded the ‘Technology Pioneer Status’ by the World Economic Forum. Earlier, in 2017, BAI had received the ‘Pharma Company of the year – SME’ for the year 2017 at the annual CPhI Pharma Awards..

 

 
Business Strategy Case Studies | Case Study in Management, Operations, Strategies, Business Environment, Case Studies
or
Business Strategy Case Studies | Case Study in Management, Operations, Strategies, Business Environment, Case Studies
or
PayPal (7 USD)

 

 

 
BACKGROUND NOTE - Next Page>>